Short description
SparingVision is a biotechnology company developing genomic medicines for the treatment of blinding inherited retinal diseases.
Description
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.
Last funding
No Way
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Paris, Ile-de-France, France, Europe
Founded on
January 1, 2016
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$34056 - 789030
Sign in for full access
Investors
Uh Ohhhh, Noway Youcantaccess, Noaccessforu, Absolutely Noaccess, Blurry Noaccess, Noway Youcantaccess, Blurry Noaccess, Noway Youcantaccess
Sign in for full access
Founders
Jose Alain Sahel, Thierry Léveillard